Testing A New Model For Personalized Drug Development
This article was originally published in RPM Report
Executive Summary
Pfizer, Genentech, AstraZeneca and Amgen drugs will be studied in a lung cancer “master protocol” set to launch March 1. The trial could revolutionize the treatment of a rare, serious disease – but advocates have an even bigger goal: “changing the entire paradigm for drug development.”
You may also be interested in...
FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control
FDA officials are enthusiastic about broad, multi-agent cancer trials built on the I-SPY model. For sponsors, the trials mean less control over the development path and ultimate value proposition for the therapy—but may have important benefits on defending high prices for truly effective new therapies.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.